Navigation Links
Biopure Operations Compliant With U.K. Manufacturing Guidelines
Date:4/11/2008

gen therapeutic approved for marketing by both the U.S. Food and Drug Administration and the European Commission, is indicated for the treatment of anemia in dogs. Biopure has sold approximately 200,000 units of Oxyglobin since 1998.

Statements in this release that are not strictly historical are forward- looking statements, including any statements implying that the company will be able to respond to the MHRA questions or that Hemopure will attain marketing authorization in the United Kingdom and including statements implying that any clinical trial will be initiated and/or carried out to completion or that study results will be as desired, and any statements that might imply that Hemopure may receive marketing approval in the UK or any other jurisdictions or for additional indications in South Africa. Actual results and their timing may differ materially from those projected in these forward-looking statements due to risks and uncertainties. These risks include, without limitation, uncertainties regarding the company's financial position, including its limited cash resources and need to raise additional capital to pursue its business, the company's ability to satisfactorily address the issues raised in the MHRA correspondence or additional issues raised at a later date, unexpected costs and expenses, delays and adverse determinations by regulatory authorities, unanticipated problems with the product's commercial use, whether or not product related, and with product distributors, sales agents or other third parties, delays in clinical trials, and the other factors identified under the heading "Risk Factors" in the Company's quarterly report on Form 10-Q filed on March 17, 2008, which can be accessed in the EDGAR database at the U.S. Securities and Exchange Commission's (SEC) website, http://www.sec.gov. The company undertakes no obligation to release publicly the results of any revisions to these forward-looking
'/>"/>

SOURCE Biopure Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Biopure Appoints New Independent Auditor
2. Biopure Completes U.K. Regulatory Agency Inspection
3. Biopure Announces 2008 First Quarter Financial Results
4. Biopure Launches Updated Website
5. Biopure Announces Pricing of Equity Offering
6. Biopure Gives Update on Malaysia Joint Venture Discussions
7. Genta Restructures Operations to Focus on Priority Initiatives
8. NxStage Appoints Tom Shea as Senior Vice President of Manufacturing Operations
9. NanoLogix Inc. Presents at the National Hydrogen Association Conference & Provides Operations, Management and Director Update
10. Mentice AB Announces Leadership Changes Within Its Worldwide Operations
11. Michael J. Simms Joins Alexza Pharmaceuticals as Senior Vice President, Operations and Manufacturing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/1/2015)... BAY HEAD, N.J. , June 1, 2015 /PRNewswire/ ... to launch a national innovative science curriculum for high ... announcement at the 16 th annual LIFE Event ... held at Mountain Ridge Country Club in ... some of the LPGA,s biggest stars raised more than ...
(Date:6/1/2015)... N.C. , June 1, 2015  Fennec ... presentation of positive interim results from a poster ... multi-centre open label randomised phase III trial of ... ototoxicity in patients receiving cisplatin (Cis) monotherapy for ... at the American Society of Clinical Oncology (ASCO) ...
(Date:6/1/2015)... and SOUTH SAN FRANCISCO, Calif. ... the venture arm of Baxter International Inc. (NYSE: ... LLC ("VPD") today announced the formation of Vitesse Biologics, ... by Baxter Ventures to focus on the development of ... hematology, and oncology. Following the spin-off of Baxter BioScience ...
(Date:6/1/2015)... June 1, 2015 Esperance Pharmaceuticals Inc. today ... lead candidate EP-100 in ovarian cancer patients resistant to ... seek and destroy cancer cells that overexpress luteinizing hormone-releasing ... over-expressed in a wide range of cancers. ... trial of EP-100 were presented at the 2015 ...
Breaking Biology Technology:Val Skinner Foundation Announces Partnership With Discovery Education 2Fennec Announces Presentation Of Positive Interim Sodium Thiosulfate Phase III Safety Data At The 2015 ASCO Annual Meeting 2Fennec Announces Presentation Of Positive Interim Sodium Thiosulfate Phase III Safety Data At The 2015 ASCO Annual Meeting 3Fennec Announces Presentation Of Positive Interim Sodium Thiosulfate Phase III Safety Data At The 2015 ASCO Annual Meeting 4Baxter Ventures, Mayo Clinic And Velocity Pharmaceutical Development Announce The Formation Of Vitesse Biologics, LLC, A Company Structured To Accelerate Therapeutic Innovation 2Baxter Ventures, Mayo Clinic And Velocity Pharmaceutical Development Announce The Formation Of Vitesse Biologics, LLC, A Company Structured To Accelerate Therapeutic Innovation 3Baxter Ventures, Mayo Clinic And Velocity Pharmaceutical Development Announce The Formation Of Vitesse Biologics, LLC, A Company Structured To Accelerate Therapeutic Innovation 4Baxter Ventures, Mayo Clinic And Velocity Pharmaceutical Development Announce The Formation Of Vitesse Biologics, LLC, A Company Structured To Accelerate Therapeutic Innovation 5Esperance Reports Positive EP-100 Phase ll Results in Ovarian Cancer at 2015 ASCO Annual Meeting 2Esperance Reports Positive EP-100 Phase ll Results in Ovarian Cancer at 2015 ASCO Annual Meeting 3
... Platypus Technologies of suburban Madison has received ... for $200,000 from the National Cancer Institute. The grant ... rapid quantification of protein activity, useful for cancer research. ... II SBIR grant for $2.14 million from the National ...
... been calls to run government institutions as a business, ... their shareholders: taxpayers. Now schools are facing similar scrutiny. ... Behind Act have expanded the federal regulations with which ... are also demanding more budget accountability at a time ...
... Inc ., a provider information management systems and services ... a definitive agreement to acquire BillMatrix Corp ., ... , ,BillMatrix, founded in 1994, provides billers with an ... immediate credit for bills paid online or over the ...
Cached Biology Technology:Looking to software to manage the business of education 2Looking to software to manage the business of education 3Looking to software to manage the business of education 4
(Date:5/8/2015)... -- Synaptics Inc. (NASDAQ: SYNA ), the leading developer ... executive management team will present at the following investor events: ... Conference Date: May 18, 2015 Time: 10:40am ET ... Cowen and Company Technology, Media & Telecom ... New York Palace Hotel, New York, NY ...
(Date:5/5/2015)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or ... mobile commerce market, reminds investors and media that  Mr. ...  at CARTES SECURE CONNEXIONS AMERICA 2015, held in ... The three-day conference is organized into a series of nine ... Global Fraud: Where is the Trust in Cyberspace? ...
(Date:4/27/2015)... LAUDERDALE, Fla. , Apr. 27, 2015 ... of access control and security systems is pleased to ... the company as a consultant and member of its ... is widely known as a thought leader in ... Distance Learning Technology Group, and has published studies and ...
Breaking Biology News(10 mins):Synaptics to Present at Upcoming Investor Conferences 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 3Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 2Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 3Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 4
... SALT LAKE CITYResearchers have discovered two enzymes that, when ... cancer. Manipulating these enzymes genetically might lead to targeted ... tumors. "We could conceivably reactivate a completely normal ... could prevent the growth of a tumor if reactivated," ...
... crimefighter who protected the innocent from pirates, hijackers and ... its costumed namesake, this electromagnetic phantoma carbon and polymer ... the National Institute of Standards and Technology (NIST) for ... The NIST phantom serves as a mannequin in a ...
... Researchers at The University of Texas School of Public Health ... of community-acquired antibiotic-resistant Staph ylococcus aureus ... (PVL). The Panton Valentine leukocidin is made ... is typically produced by community-acquired methicillin-resistant S. aureus ...
Cached Biology News:Newly found enzymes may play early role in cancer 2Electromagnetic phantom exorcises specters of metal detector tests 2UT Public Health researchers find link to severe Staph infections 2
... 2500ml narrow mouth PYREX low form culture flask is ... to volume ratio. This flask has a heavy beaded ... marking spot. The neck O.D. is 38mm and takes ... use this flask on a heat source smaller than ...
... The loxP-amp-loxP cassette is ... cells. The prokaryotic promoter gb2 driving ... slightly modified version of the Em7 promoter. ... generally used Tn5 promoter. A synthetic polyadenylation ...
... is designed to allow ampicillin selection in ... driving the gene for ampicillin resistance is ... promoter. It mediates higher transcription efficiency than ... polyadenylation signal terminates the ampicillin expression. The ...
... for the fast and simple integration of ... position (for the generation of transgenic mouse ... to allow neomycin / kanamycin selection in ... prokaryotic promoter (gb2) for expression of kanamycin ...
Biology Products: